BACKGROUND: @entity1125 ( @entity1125 ) is a rare and lethal disease with few therapeutic options. Preclinical data suggest that the @entity470 ( @entity470 ) pathway could be involved in its progression. METHODS: This open-label, randomized phase 2 trial recruited chemotherapy-naive @entity1 with advanced @entity1125 displaying a wild-type (WT) @entity984 status. @entity1 were randomized to @entity136 (1000   mg/m(2) ) and @entity901 (100   mg/m(2) ) with (arm A) or without (arm B) panitumumab (6   mg/kg) for up to 12 cycles. The primary endpoint was progression-free survival (PFS) analyzed in an intention-to-treat fashion. RESULTS: Eighty-nine @entity1 (45 in arm A and 44 in arm B) were enrolled between June 2010 and September 2013. After a median follow-up of 10.1 months, the median PFS was 5.3 months (95% confidence interval, 3.3-7.2 months) in arm A and 4.4 months (95% confidence interval, 2.6-6.2 months) in arm B (P   =   .27). No survival differences were observed: the median overall survival was 9.9 months in arm A and 10.2 months in arm B (P   =   .42). In a subgroup analysis, no differences in PFS according to the site of the primary @entity5 were observed; @entity1 with @entity1419 treated with panitumumab may have had a survival benefit in comparison with the control group (15.1 vs 11.8 months, P   =   .13). As for safety, @entity137 was the main adverse event in arm A (80% of the @entity1 ). A higher incidence of @entity294 (55.5% vs 31.8%), @entity33 (22.2% vs 13.6%), and @entity1142 (24.4% vs 15.9%) was seen in arm A. CONCLUSIONS: These results confirm the marginal role of anti- @entity470 therapy even for WT @entity984 -selected @entity1125 . @entity5 2016;122:574-581.    2015 American @entity5 Society.

Panitumumab in combination with @entity136 and @entity901 does not prolong survival in wild-type @entity984 advanced XXXX : A randomized phase 2 trial (Vecti-BIL study).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['skin toxicity'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Cancer'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity1419 :: ('MESH:C535533', 'Disease') :: ['intrahepatic cholangiocarcinoma'] @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1125 :: ('MESH:D001661', 'Disease') :: ['BTC', 'Biliary tract cancer']
@entity1125 :: (MESH:D001661,Disease) :: ['biliary tract cancer']
